Overview

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is a 2-part study. Part 1 is to determine the safety and tolerability in healthy participants of increasing daily doses of LY2484595 for 14 days to achieve a blood level of LY2484595 much higher than what is needed for therapy. The amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it will be determined. The effect of the study drug on factors in the blood related to cholesterol will be measured. Part 2 is to determine how ketoconazole affects how much of the study drug, LY2484595, gets into the bloodstream and how long it takes to get rid of it. Information about any side effects that may occur will also be collected.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Evacetrapib
Ketoconazole